N/A N=11 Premie Pouch to Manage Deformational Plagiocephaly in Very Low Birth Weight Infants
Plagiocephaly
Primary: Safety of Use of the Premie Pouch in VLBW Infants — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=575 Persistent Pain After CS Delivery
Persistent Pain After Delivery
Primary: Persistent Pain-PERCEIVED STRESS Scores Stratified by the Rate of Recovery — 11.4; 12.9; 15.4 units on a scale — p=<0.01
N/A N=20 The Metaphyseal Hip Prosthesis - Total Hip
Osteoarthritis of the Hip
Primary: RSA Translation X — 0.05; 0.05; 0.10; 0.08 mm
Phase 3 N=405 ProQuad® Intramuscular vs Subcutaneous
Measles · Mumps · Rubella
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment — 100; 100; 99.3; 99.3 Percentage of participants
Phase 1 N=113 Study of LC23-1306 in Healthy Male Subjects
Acute Coronary Syndrome
Primary: Adverse Events of LC23-1306
Phase 2 N=415 A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Type 2 Diabetes Mellitus and Microalbuminuria
Primary: Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12) — 0.152; -0.173…
Phase 2 N=57 Efficacy and Tolerability of an Intra-Nasal Testosterone Product
Hypogonadism
Primary: Serum Testosterone Ln-Cmax — 6.25; 6.41; 6.54; 6.36 ng/dL
Phase 2 N=27 Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
Healthy Volunteers
Primary: Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity — -3.57; -70.80; -60.83; -69.85 Percent change…
Phase 2 N=110 Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
Tuberculosis
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 38; 40; 9; 1 Participants
Phase 2 N=253 Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder
Female Orgasmic Disorder
Primary: Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period — 2.8; 3.9; 3.2; 1.9 orgasms
Phase 2 N=206 Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
Cellulitis
Primary: The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid. — 6; 4 Participants
Phase 4 N=20 Internet Surveys and Their Impact on Adherence for Rosacea
Rosacea
Primary: Adherence (% of Prescribed Doses That Were Actually Taken by the Subject) — 8.2; 6.9 percentage of medication use
Phase 3 N=227 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Psoriasis · Plaque Psoriasis
Primary: Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16 — 11.6; 81.4; 82.6 percentage of participants — p=<0.0001
Phase 1 N=56 Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 6; 8 Participants
Phase 2 N=177 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
Primary: Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 — -2.46; -2.55; -1.17; 0.09 Percentage change — p=0.0127